source
- STAT+: Influential preventive services panel to meet for first time in more than a yearA task force, meeting after a long delay, will discuss coverage of treatments for cervical cancer, perinatal depression, and alcohol use.
- Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trialSellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…